Omar Alhalabi

Jul 2, 2024 | urotoday.com | Omar Alhalabi

Read the Full Video TranscriptAshish Kamat: Hello everyone and welcome to UroToday's Bladder Cancer Center of Excellence. I'm Ashish Kamat, Professor of Urologic Oncology at MD Anderson Cancer Center. And it's a distinct pleasure to welcome one of my colleagues, Omar Alhalabi, who is a medical oncologist right across the hall actually from me. And we actually share a clinic and we share bladder cancer patients. And it's a great privilege and pleasure to have you on the forum, Omar.

Apr 18, 2023 | nature.com | Omar Alhalabi |Roman Groisberg |Andrew Hahn |Aung Naing |Apostolia M. Tsimberidou |Timothy A. Yap | +2 more

AbstractPre-clinically, the mTORC1/2 inhibitor sapanisertib restored sensitivity to platinums and enhanced paclitaxel-induced cancer cell killing. NCT03430882 enrolled patients with mTOR pathway aberrant tumors to receive sapanisertib, carboplatin and paclitaxel. Primary objective was safety and secondary objectives were clinical response and survival. One patient had a dose-limiting toxicity at dose level 4. There were no unanticipated toxicities.